Brickell biotech, inc. (VICL)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Current assets:
Cash and cash equivalents

7,100

7,232

7,225

10,813

11,259

8,067

12,101

10,071

10,110

24,841

10,210

4,614

4,564

5,069

8,460

5,229

5,927

13,450

18,741

19,667

17,666

20,471

22,660

31,793

40,756

38,837

38,811

45,033

47,026

43,159

53,150

65,717

70,475

38,696

41,068

24,611

47,320

Marketable securities, available-for-sale

0

4,497

18,473

30,907

34,272

0

-

-

-

35,658

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

5,765

6,240

5,034

-

-

204

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Marketable securities, available-for-sale

-

-

-

-

-

-

38,267

41,832

45,814

-

22,629

27,249

29,216

30,552

28,990

27,746

28,938

23,258

19,864

18,892

23,385

23,499

23,869

14,624

7,096

11,541

17,036

19,406

25,352

37,639

33,743

26,099

20,787

8,733

11,565

12,302

5,037

Restricted cash

-

-

-

-

-

-

192

192

192

192

192

3,311

3,311

3,311

3,311

3,246

3,246

3,246

3,246

3,182

3,182

3,182

3,182

3,119

3,119

3,119

3,119

3,059

3,059

3,059

3,059

2,998

2,999

2,998

2,999

2,911

2,911

Deferred contract costs

-

-

-

-

-

-

0

-

-

10,502

9,574

8,447

7,163

5,513

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables and other assets

-

-

-

979

826

-

1,916

1,610

1,445

5,124

2,745

2,898

2,943

3,422

6,249

4,751

4,161

4,544

5,769

4,697

3,709

4,178

4,689

4,532

4,377

4,590

1,829

2,083

2,390

2,152

2,537

3,777

13,541

3,130

2,642

1,063

940

Total current assets

12,892

17,969

30,732

42,699

46,357

8,271

52,476

53,705

57,561

76,317

45,350

46,519

47,197

47,867

47,010

40,972

42,272

44,498

47,620

46,438

47,942

51,330

54,400

54,068

55,348

58,087

60,795

69,581

77,827

86,009

92,489

98,591

107,802

53,557

58,274

40,887

56,208

Long-term investments

-

-

-

0

0

-

2,190

2,237

2,176

2,209

2,189

2,159

2,108

2,046

2,217

2,238

2,182

2,052

2,077

1,980

2,034

1,971

1,937

1,994

1,968

1,980

2,039

2,037

2,197

2,225

2,250

2,198

2,128

5,928

5,915

5,567

5,434

Property and equipment, net

13

16

20

2

86

37

117

165

562

606

598

749

964

1,173

1,375

1,578

1,681

1,873

2,010

2,207

2,427

2,639

2,857

3,156

3,548

3,935

4,353

4,735

5,042

5,284

5,572

5,873

5,968

6,226

6,654

6,966

7,560

Operating lease right-of-use asset

133

159

176

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets, net

-

-

-

-

-

-

0

-

416

703

730

757

784

810

838

868

902

1,300

1,522

1,565

1,596

1,660

1,702

-

-

1,972

-

-

-

-

-

-

-

-

-

-

-

Intangible assets

-

-

441

-

-

441

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,994

2,023

-

2,115

2,741

2,742

2,813

2,822

2,862

2,848

2,871

3,012

3,094

3,247

Other assets

-

-

-

0

0

-

844

659

659

659

747

599

388

388

388

191

191

191

191

191

379

379

379

379

379

379

192

191

191

191

192

192

191

191

192

191

458

Total assets

13,038

18,144

31,369

42,701

46,443

8,749

55,627

56,766

61,374

80,494

49,614

50,783

51,441

52,284

51,828

45,847

47,228

49,914

53,420

52,381

54,378

57,979

61,275

61,591

63,266

66,353

69,494

79,285

87,999

96,522

103,325

109,716

118,937

68,773

74,047

56,705

72,907

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

1,137

2,245

1,291

-

-

4,067

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

5,124

6,379

3,475

-

-

3,272

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability, current portion

80

78

75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

1,159

2,521

-

3,522

3,161

3,070

5,217

4,078

3,780

3,539

4,127

3,853

3,191

3,544

3,912

3,364

4,025

4,099

5,201

4,600

3,716

3,220

3,503

5,173

5,984

5,109

5,629

5,591

5,064

7,266

6,362

5,484

5,618

6,334

Deferred revenue

750

1,795

2,464

0

0

8,117

10

20

-

11,700

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable

-

-

0

-

-

4,639

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

86

-

7,803

7,203

5,316

3,018

112

122

84

250

2,110

520

30

0

38

75

113

150

37

75

167

150

0

-

-

99

-

51

-

Total current liabilities

7,091

10,497

7,305

1,159

2,521

20,095

3,532

3,181

3,156

16,917

11,881

10,983

8,855

7,145

3,965

3,313

3,628

4,162

5,474

4,545

4,129

5,201

4,638

3,791

3,333

3,653

5,210

6,059

5,276

5,779

5,591

5,064

7,266

6,461

-

5,669

6,334

Lease liability, net of current portion

53

73

94

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contingent consideration

-

-

145

-

-

145

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

0

-

-

242

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

0

-

-

1,595

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development funding liability

-

-

5,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total liabilities

7,144

10,570

13,144

-

-

22,077

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Redeemable convertible preferred stock (Series A, B, C and C-1), $0.01 par value, 5,000,000 and 4,182,943 shares authorized at December 31, 2019 and 2018, respectively; 0 and 1,256,466 shares issued and outstanding at December 31, 2019 and 2018, respectively; aggregate liquidation preference of $0 and $46,985 at December 31, 2019 and 2018, respectively

-

-

0

-

-

58,290

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

90

225

359

494

618

737

856

974

1,082

1,185

1,288

1,391

1,483

1,569

1,657

1,743

1,820

1,892

1,964

2,036

2,097

2,211

Commitments and contingencies (Note 6)

-

-

-

-

-

-

-

-

-

0

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000 shares authorized, none issued and outstanding

-

-

-

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, $0.01 par value, 50,000,000 shares authorized at March 31, 2020 and December 31, 2019; 9,671,904 and 8,480,968 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

97

85

78

229

229

6

218

218

218

218

115

112

111

111

110

92

920

92

915

914

914

903

902

878

868

868

868

865

863

861

861

860

859

719

719

718

716

Additional paid-in capital

-

-

-

490,343

490,318

-

490,244

490,185

490,023

489,975

460,501

459,518

459,017

458,881

458,698

450,752

449,648

450,166

448,976

448,541

448,019

446,698

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in capital

94,880

92,497

92,276

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

445,843

442,489

440,516

439,708

438,939

437,844

437,276

435,915

435,253

434,409

433,528

384,087

383,282

382,469

380,929

Accumulated other comprehensive loss

0

-28

-11

42

17

0

91

130

57

122

127

93

61

25

161

183

135

40

111

13

67

-12

-48

21

-6

11

69

134

234

247

265

225

186

580

950

607

472

Accumulated deficit

-89,100

-84,980

-74,100

-449,072

-446,642

-71,624

-438,458

-436,948

-432,080

-426,738

-423,010

-419,923

-416,603

-413,878

-411,106

-408,583

-407,328

-404,905

-402,550

-402,250

-399,488

-395,667

-391,034

-386,670

-382,630

-379,175

-376,983

-367,100

-357,219

-347,937

-340,388

-332,662

-324,794

-325,038

-318,424

-334,855

-317,755

Stockholders' Equity Attributable to Parent

5,894

7,574

18,225

41,542

43,922

-71,618

52,095

53,585

58,218

63,577

37,733

39,800

42,586

45,139

47,863

42,444

43,375

45,393

47,452

47,218

49,512

51,922

55,663

56,718

58,748

61,412

62,893

71,743

81,154

89,086

95,991

102,832

109,779

60,348

66,527

48,939

64,362

Total liabilities and stockholders’ equity

13,038

18,144

31,369

42,701

46,443

8,749

55,627

56,766

61,374

80,494

49,614

50,783

51,441

52,284

51,828

45,847

47,228

49,914

53,420

52,381

54,378

57,979

61,275

61,591

63,266

66,353

69,494

79,285

87,999

96,522

103,325

109,716

118,937

68,773

74,047

56,705

72,907